From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|April 20, 2018
Novel Oral Anticoagulant Reversal Agent Tops AJPB Week in Review
Author(s)AJPB staff
Top news of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. FDA OKs Treatment Combo for Advanced Renal Cell Carcinoma
Nivolumab plus low-dose ipilimumab combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced renal cell carcinoma. Read more.
4. Congress, Medical Societies Address Approaches to Combat Opioid Crisis
Two different approaches to attack the opioid-fueled substance use disorder (SUD) crisis are on display this week. Read more.
3. Artificial Pancreas Improves Blood Sugar Control in Type 1 Diabetes
An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study. Read more.
2. Childhood Factors May Contribute to COPD Risk
Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies. Read more.
1. FDA Approves First Novel Oral Anticoagulant Reversal Agent
The approval is the first of its kind for a reversal agent of a novel oral anticoagulant (NOAC). Read more.
Advertisement
Related to this article
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5